OncologyInformationService
Real World Databases
Evidence based Healthcare and Market Research
logo
O.I.s) has become
TriNetX Oncology GmbH,
our new website is coming soon!
Multiple Myeloma
  • Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD-38 from a German registry
    Goldschmidt H., Merz M., Hari P., Agha M., Diels J., Ghilotti F., Haefliger B., C Sakabedoyan C., Bacon T., Schecter J., Jackson C., Olyslager Y., Carrasco-Alfonso MJ., Nesheiwat T., Kellermann L., Jagannath S., Poster EHA 2021 --> PDF
  • Baseline characteristics and survival outcomes of patients with tri exposed multiple myeloma in a German registry
    Haefliger B., Diels, J., Ghilotti F., Sliwka H., Potamianou A., Bacon T., Kellermann L., Poster EHA 2021 --> PDF
  • Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma in Europe from 2016 to 2018:Analysis of a Multi-National Survey
    Maximilian Merz, Isabelle Vande Broek, Manuel Pérez, Brigitte Kolb, Argiris Symeonidis, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, Hartmut Goldschmidt, Poster ASH 2019 --> PDF
  • Treatment Patterns in Patients with Refractory/Relapsed Multiple Myeloma in Germany Between 2016 and 2018
    Maximilian Merz, Vishal Patel, Lucie Kutikova, Andrea Lebioda, Martina Schoehl, Lenka Kellerman, Hartmut Goldschmidt, Poster ASH 2019 --> PDF
  • Diagnostic and therapeutic approaches to multiple myeloma patients: ‘Real-world’ data from representative multicentre treatment surveys in Germany between 2008 and 2011
    THOMAS M. MOEHLER, MAXIMILIAN MERZ, LENKA KELLERMANN, HARTMUT GOLDSCHMIDT and WOLFGANG KNAUF, Oncology Letters Vol 12 No 6, p.5043-5051, 2016 --> PDF
  • Diagnosis and treatment of multiple myeloma in Germany – Analysis of a nationwide, multi-institutional survey
    Maximilian Merz, Lenka Kellermann, Wolfram Poenisch, Hans-Joachim Tischler, Joern Kohnke, Wolfgang Knauf and Hartmut Goldschmidt, Poster DGH0 2016 --> PDF
  • Comparative Effectiveness of Pomalidomide Plus Low-Dose Dexamethasone (POM+LoDEX) in Relapsed and Refractory Multiple Myeloma: Use of Real-World Data in the Absence of Head-to-Head Studies
    Hartmut Goldschmidt, Rebecca Harvey, Dawn Lee, Sujith Dhanasiri, Pellegrino Musto, Sergio Storti, Lucia Pantani, Lenka Kellermann, Brigitte Kolb, Gordon Cook --> PDF
  • Treatment of Multiple Myeloma in Germany
    An update of a representative multicentre health care survey 2004‐2011 Knauf Wolfgang, Kellermann Lenka, David Bórquez, Brendel Kurt, Buschmann Dirk, Ehlers Thomas, Görg, Christian, Poenisch Wolfram, Goldschmidt Hartmut --> PDF
  • How to Treat Multiple Myeloma – A Representative Mulicentre Treatment Survey
    Wolfgang Knauf, Lenka Kellermann, Wolfgang Poenisch, Hermann Einsele, Christian Straka, Claas Frohn, Hartmut Goldschmidt. --> PDF
    Zeitschrift Onkologie Vol. 33, No.11, 2010, S.604-610 --> Link
  • Use of New Treatment Options in Multiple Myeloma
    Ergebnisse einer repräsentativen multizentrischen Erhebung 2006 R. Angermund, W.Knauf, M.Freund, M.Nowrusian, H. Einsele, H. Goldschmidt, W. Berdel, W. Poenisch, C. Straka, L. Kellermann, H. Pliskat --> PDF
  • Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany
    Mathias R.F. Freund, W. Knauf, H. Goldschmidt, H. Einsele, M. R. Nowrousian, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer, R. Angermund. ASH 47th annual meeting Atlanta 2005, Publication Only, Abstract 5158 --> PDF
  • Role of Bortezomib in the Treatment of Multiple Myeloma – First Results from a Representative Multicentre Treatment Survey in Germany (GER)
    Ralf Angermund, W. Knauf, M. Freund, M. R. Nowrousian, H. Einsele, H. Goldschmidt, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer. ASH 47th annual meeting Atlanta 2005, Publication Only, Abstract 5156 --> PDF
Non Hodgkin Lymphome
  • Treatment of Chronic Lymphocytic Leukemia in Germany
    Results of a representative population‐based survey in 2011 Zoellner A.‐K., Höhler T., Fries S., Böhme A.A., Kiewe P., Kellermann L., Dreyling M. --> PDF
  • Indolente Non Hodgkin Lymphome – Trends in diagnosis and therapy in Germany
    Schmidt C., Fingerle-Rowson G., Boehme, Brendel K., Fischer R., Gonnermann M., Höhler T., Kegel T., Kellermann L., Nusch A., Pönisch W., Woitinas F., Wendtner C.-M., Dreyling M. --> PDF
  • Treatment of Indolent Lymphomas in Germany
    Ergebnisse einer repräsentativen multizentrischen Erhebung 2006 M. Dreyling, S. Fetscher, Ch. Görg, M. Kornek, M. Nusch, M. Kornacker, R. Angermund, H. Pliskat, L. Kellermann, T. Kegel --> PDF
Myelodisplactic Syndrome
  • Real-world data in a German healthcare survey demonstrate a high medical need of patients with lower risk MDS and ringsideroblasts.
    Kaivers J., Garz A.-K., Kellermann L., Frank M., Ludäscher M., Schackert N., Gattermann N., Germing U., Poster DGHO 2020 --> PDF
  • First Results of a Multicentre Retrospective Analysis of Diagnosis and Treatment of MDS Patients in Germany
    N. Gattermann1, A. Kündgen1, L. Kellermann2, M. Zeffel3, N. Lang3, U. Germing1 1 Heinrich-Heine-Universität Düsseldorf, 2 Oncology Information Service Freiburg, 3 Celgene GmbH München. --> PDF
    The resultes were presented as a poster at the DGHO Jahrestagung 2010 in Berlin. --> Link
Gastric Cancer
  • Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
    Kirsten Merx, Manuel Barreto Miranda, Lenka Kellermann, Ulrich Mahlknecht, Oliver Lange, Michael Gonnermann, and Ralf-Dieter Hofheinz --> PDF
    Gastroenterology Research and Practice, Volume 2016, Article ID 1028505, 7 pages --> Link
  • Metastatic Esophagogastric Adenocarcinoma: Trends in First-Line Treatment and Predictive Factors for the Implementation of HER2 Testing in Clinical Practice During the First Year after Trastuzumab Market Approval
    Deniz Gencer, Salah-Eddin Al-Batran, Reyad Dada, Ali-Nuri Hünerlitürkoglu, Michael Gonnermann, Thomas Kegel, Harald Scheiber, Wolf-Oliver Jordan, Iris Burkholder, Lenka Kellermann, Ralf-Dieter Hofheinz.
    Journal of Cancer Res Clin Oncol. 2013 Feb;139(2):337-45 --> Link
  • Population-Based Patterns of Care in the First-Line Treatment of Patients with Advanced Esophagogastric Adenocarcinoma in Germany
    R.-D. Hofheinz, S.-E. Al-Batran, K. Ridwelski, C. Görg, K. Wehle, M. Birth, S. Fetscher, H. Scheiber, N. Lukan, F. Lordick --> PDF
    Published in: Zeitschrift Onkologie Vol. 33, No.10, 2010, S. 512-518 --> Link
  • Population-Based Patterns of Care in the Treatment of 678 Patients with Gastric Cancer
    Hofheinz, R; Al-Batran S.; Kellermann, L.; Arnold, D. in: Onkologie 2006;29 (suppl3), S. 11-12 --> PDF
Colorectal Cancer
  • Did the uptake of new treatment options change the treatment strategy in patients with colorectal cancer and primary non-resectable metastases?
    The results of large population-based survey in Germany 2005-2007 Lenka Kellermann, Dirk Arnold, Salah-Eddin Al-Batran, Hans-Joachim Schmoll --> PDF
  • Deficiencies in the Treatment of Colorectal Cancer Patients in Germany
    Axel Grothey, Lenka Kellermann, Hans - Joachim Schmoll, in: Medizinische Klinik, Vol.97, Nr. 5 Mai 2002, S. 270- 277 --> PDF
Prostate Cancer
  • SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC) in Germany
    Axel S. Merseburger, Lenka Kellermann, Andreas Janitzky, Martin Hatzinger, Susan Feyerabend, Christiana Lütter, Katrin Krützfeldt, Marina Akkermann, Natasha Schuier Poster presented at the 8th European Multidisciplinary Meeting on Urological Cancers, Milan, Italy 2016 --> PDF
Ovarian Cancer
  • Treatment of Advanced Ovarian Cancer in Germany
    A. du Bois, J. Pfisterer, L. Kellermann, in: Der Onkologe, Vol.8, Part. 11 2002, S. 2101-1215 --> PDF
Lung Cancer
  • Disparities in Access to EGFR‐Mutation Testing in Patients with Advanced NSCLC in Germany 2011
    Lenka Kellermann, Dieter Ukena The results were presented in a poster at the ISPOR Annual European Congress 2012. --> PDF